It demonstrates that TDQ treatment, associated with increased hepatic PPARγ and reduced DGAT2 expression, targets multiple risk factors of the type 2 diabetes; additionally, it is a glucose- and lipid-lowering agent with a strong ability to treat diabetic complications. The gene discussed is DGAT2; the disease is type 2 diabetes mellitus.